Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.42 | 29.62 | -0.11 | 0.18 |
| FCF Yield | 0.47% | -7.54% | -18.25% | -31.38% |
| EV / EBITDA | -42.07 | -9.00 | -5.18 | -6.96 |
| Quality | ||||
| ROIC | -16.24% | -19.59% | -43.20% | -68.44% |
| Gross Margin | 75.77% | 74.76% | 83.94% | 90.06% |
| Cash Conversion Ratio | -0.12 | 0.43 | 0.89 | 1.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 63.51% | 113.55% | – | – |
| Free Cash Flow Growth | 110.25% | 24.38% | 20.67% | -69.97% |
| Safety | ||||
| Net Debt / EBITDA | -1.95 | -0.16 | 0.21 | 0.44 |
| Interest Coverage | -6.12 | -7.23 | -8.21 | -9.86 |
| Efficiency | ||||
| Inventory Turnover | 3.64 | 2.11 | 2.22 | 1.26 |
| Cash Conversion Cycle | 119.62 | 248.70 | 21.47 | -1,405.56 |